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ABSTRACT

Berberine, which has a long history of use in Chinese medicine, has recently been
shown to have efficacy in the treatment of diabetes. While the hypoglycemic effect of
berberine has been clearly documented in animal and cell line models, such as 3T3-L1
adipocytes and L6 myotube cells, the mechanism of action appears complex with data
implicating activation of the insulin signaling pathway as well as activation of the
exercise or AMP kinase-mediated pathway. There have been no reports of the acute
affects of berberine on the transport activity of the insulin-insensitive glucose transporter,
GLUT1. Therefore, we examined the acute effects of berberine on glucose uptake in
L929 fibroblast cells, a cell line that express only GLUT1. Berberine- activated glucose
uptake reaching maximum stimulation of five-fold at >40 μM. Significant activation (P <
0.05) was measured within 5 min reaching a maximum by 30 min. The berberine effect
was not additive to the maximal stimulation by other known stimulants, azide, methylene
blue or glucose deprivation, suggesting shared steps between berberine and these
stimulants. Berberine significantly reduced the Km of glucose uptake from 6.7 ± 1.9 mM
to 0.55 ± 0.08 mM, but had no effect on the Vmax of uptake. Compound C, an inhibitor
of AMP kinase, did not affect berberine-stimulated glucose uptake, but inhibitors of
downstream kinases partially blocked berberine stimulation. SB203580 (inhibitor of p38
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MAP kinase) did not affect submaximal berberine activation, but did lower maximal
berberine stimulation by 26%, while PD98059 (inhibitor of ERK kinase) completely
blocked submaximal berberine activation and decreased the maximal stimulation by 55%.
It appears from this study that a portion of the hypoglycemic effects of berberine can be
attributed to its acute activation of the transport activity of GLUT1.
Nitroxyl (HNO) is a molecule of significant interest due to its unique
pharmacological properties, particularly within the cardiovascular system. A large
portion of HNO biological effects can be attributed to its reactivity with protein thiols,
where it can generate disulfide bonds. Evidence from studies in erythrocytes suggests that
the activity of GLUT1 is enhanced by the formation of an internal disulfide bond.
However, there are no reports that document the effects of HNO on glucose uptake.
Therefore, we examined the acute effects of Angeli’s salt (AS), a HNO donor, on glucose
uptake activity of GLUT1 in L929 fibroblast cells. We report that AS stimulates glucose
uptake with a maximum effective concentration of 5.0 mM. An initial 7.2-fold increase
occurs within 2 min, which decreases and plateaus to a 4.0-fold activation after 10 min.
About 60% of the 4.0-fold activation recovers within 10 min, and 40% remains after an
hour. The activation is blocked by the pretreatment of cells with thiol-reactive
compounds, iodoacetamide (0.75 mM), cinnamaldehyde (2.0 mM), and phenylarsine
oxide (10 μM). The effects of AS are not additive to the stimulatory effects of other acute
activators of glucose uptake in L929 cells, such as azide (5 mM), berberine (50 μM), or
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glucose deprivation. These data suggest that GLUT1 is acutely activated in L929 cells by
the formation of a disulfide bond, likely within GLUT1 itself.
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CHAPTER I
INTRODUCTION
Glucose is an important source of energy for a wide variety of living organisms.
Body tissues, such as the brain, continually need constant supply of glucose. Low blood
glucose can result in loss of consciousness, seizures and possibly death. However,
prolonged increases in the concentration of blood glucose such as in poorly controlled
diabetes results in renal failure, blindness, peripheral and cardiovascular disease, and
neuropathy. Therefore, there is need to maintain the concentration of blood glucose
within narrow limits. This can be achieved either by natural physiological processes or by
introduction of safe pharmaceutical agents, which mimic the physiological processes and
yield the same results. In the long run this manages hyperglycemia and more specifically,
diabetes.
Diabetes mellitus is a heterogeneous disorder characterized by the derangement of
carbohydrates, protein and lipid metabolism (Yin et al., 2008; Rother., 2007; Muueckler.,
1990). In the year 2005 there was an increase in the incidence of diabetes and at least 190
million people were diagnosed with the ailment worldwide (Ravid and Rachmani., 2005).
Presently, recent studies show a total of 300 million people with the ailment (IDF, 2011).
Diabetes can be classified into two types; type-1 and type-2.
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Diabetes mellitus type-1 is characterized by loss of the insulin-producing beta
cells of the islets of Langerhans in the pancreas resulting to insulin deficiency. Type-1
diabetes can be further classified as immune-mediated or idiopathic. The majority of
type-1 diabetes is of the immune-mediated nature, where beta cell loss is a T-cell
mediated autoimmune attack (Rother., 2007).
Diabetes mellitus type-2, which is the focus of this study is the more common
type of diabetes and is characterized by cell insulin resistance, which may be combined
with reduced insulin secretion (Rother., 2007).
Hyperglycemia is the common effect of both of these abnormalities. The
defective responsiveness of body tissues to insulin is believed to involve the insulin
receptor (Rother., 2007). Although the specific physiologic and genetic causes for insulin
resistance are not fully understood; the predominant abnormality in the early stage of
diabetes is reduced insulin sensitivity, which can be the result of genetic defects
anywhere in the insulin-signaling pathway. At this stage hyperglycemia can be reversed
by a variety of measures and medications. These treatments improve insulin sensitivity
or reduce glucose production by the liver and enhance glucose uptake in the body tissues
(Rother., 2007).
There is no absolute cure for diabetes type-1 and type-2, though significant
success has been demonstrated with insulin administration either orally or intravenously
(Goldfine and Youngren.1998), but like all proteins, insulin is usually degraded which
results in destruction of its activity (Goldfine and Youngren., 1998 and Al-Awaidi etal.,
1985). In addition, Oral hypoglycemic agents like sulphonylureas and biguanides (Al-
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Awaidi etal., 1985) and other currently available drugs pose significant side effects and
high rate of secondary failure [8,10,11] (Rother., 2007; Al-Awaidi etal., 1985 and Xie et
al., 2005). Thus, there is need for further research to find new oral medication for longterm control of blood glucose in diabetes type-2 patients. The hallmark characteristic of
diabetes is compromised glucose uptake; thus, there is high interest in nutrichemicals or
plant products and other potential biopharmaceutical agents that activate glucose uptake
as potential treatments for diabetes. There has been wide use of certain plant products
generally regarded as safe that manage diabetes due to their anti- oxidation, anti-obesity
and anti-hyperglycemia properties (Yin et al., 2008). However, quality control in these
plants is difficult as there are often several pharmacologically active components present
in the extracts, each with unique medicinal effects. Consequently, for the purpose of
scientific investigation, it is better to work with purified components. In this study, we
have considered berberine, a purified isoquinoline compound, found in some medicinal
plants such as coptis chinensis, and hydrastis canadensis. In addition, we have also
considered nitroxyl (HNO), a potential biopharmaceutical that has recently received great
attention because of its ability to form disulfide bonds in thio-proteins and hemeproteins
which implicates HNO as a potential cell signaling molecule (Fukuto et al., 2005). We
have investigated their potential medicinal properties, particularly the antihyperglycemia properties: activation of glucose uptake, and for HNO in particular; the
effects on the structure of GLUT1, the ubiquitous glucose transporter focused in this
study, which also contains cysteine groups in its structure (figure 1.0a & 1.0d).
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GLUCOSE UPTAKE TRANSPORTERS
The fact that glucose, a monosaccharide, is an important energy source for a wide
variety of cells cannot be over emphasized. The polarity of glucose prohibits simple
diffusion across the membrane, and therefore, the transport of glucose into cells requires
protein transporters. The most common mammalian glucose transporters are a family of
passive transmembrane protein characterized of having twelve transmembrane spanning
helices (Figure 1.0b)
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Figure 1.0 Structural representations of Glut1. (a) Side view showing relative positions
of the helices. Residues in red represent topology constraints derived from experimental
results involving N45, K300, and C429 for the extracellular side, and motifs
89RFGRR93 and 330RAGRR for the cytoplasmic side. Glut1 measures ~35.6 × 26.3 Å
viewed from the top, and 46.2 Å × 27.2 Å from the bottom. Its height is ~61 Å. (b) View
from the extracellular side showing the tilt of the 12 transmembrane helices. X marks
loops entering, whereas dots mark loops exiting. (c) Cytoplasmic view; marks as above.
(d) Structure showing cysteine (yellow balls) 133, 201, 207, 347, 421 & 429 residues.
The helix colors are in concordance with the symmetry template found by Hirai et al.
(2002). Figure drawn using PYMOL (http://pymol.sourceforge.net.)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304772/
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Research has shown that five major mammalian glucose transporters (GLUT1, 2,
3, 4 &5) are selectively distributed on specific tissues (Palfreyman et al., 1992) (see table
1). Additionally, it has been suggested that the abundance of a particular isoform, in a
particular tissue cell membrane, can be correlated to its properties of kinetic transport
(Palfreyman et al., 1992). This kinetic activity, further explains the responsiveness and
sensitivity of the transporter to glucose, expressed in terms of Vmax and the Michelis Menton constant Km, respectively (Mueckler., 1990 and Pilch., 1990). For instance, In
vitro cloned culture cells demonstrate high GLUT1 isomer concentrations (Palfreyman et
al., 1992). In addition, oncogene cell transformation, growth factors, and starvation
(Louters et al., 2006) significantly increase the concentration, or the sensitivity and
responsiveness of these transporters, resulting in enhancement of glucose transport across
the plasma membrane (Palfreyman et al., 1992).
Arguably, the two most important members of the GLUT family are GLUT1 and
GLUT4.

7

http://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1393&context=gsbs_diss
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The Glucose Transporter-4 (GLUT4)
GLUT4 is the only insulin-responsive glucose transporter and is located primarily
in muscles and adipocytes (table 1). The Michaelis-Menton constant (Km) of GLUT4 for
glucose has been demonstrated to be (2-10 mM) (Palfreyman et al., 1992) and the
translocation of this isoform to the cell surface of muscle and adipose cells is stimulated
by both insulin and exercise (Palfreyman et al., 1992).
Studies on rat 3T3-L1 adipocytes show that exposure of these cells to insulin results in a
large (in excess of 20- fold) increase in the rate of glucose uptake by these cells (Gwyn.,
1997 and James et al., 1986). This increase is the result of an increased Vmax of
transport with little or no change in Km.
Insulin stimulated glucose uptake into adipocytes and skeletal muscles, is
primarily mediated by the translocation of the insulin responsive glucose transporter
GLUT4, from an intracellular compartment to the plasma membrane, as well as other
metabolic processes like glycogen synthesis and fatty acid metabolism as shown in figure
1.1, (Birmbaum., 1992). As a result of insulin response, GLUT4-containing vesicles
move to and fuse with the plasma membrane of the cell, thereby resulting in increased
total number of transporters on the cell membrane 10-40 fold (Birmbaum., 1992) as
shown on Figure 1.2.
The insulin dependent intracellular signaling events, relies substantially on the
mechanism of action of classical insulin receptors (Gwyn., 1997). These receptors are
expressed fairly ubiquitously, but with significant variation in the number of receptors
per cell, which determines responsiveness of the cell to insulin (Gwyn., 1997). These

9

receptors also have two substrates termed insulin receptor substrates (IRS1 and 2). The
discovery of IRS1 and IRS2 as major substrates of the insulin receptor paves a key way
in elucidating the early events in insulin signaling (figure 1.2) (White et al., 1985 and Sun
et al., 1995). Furthermore, since the discovery of the IRS systems, considerable studies
have been done to investigate which of these molecules, IRS1 or 2, mediate insulin’s
stimulation of glucose uptake.
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Figure 1.1 Insulin triggers the uptake of glucose via GLUT4
Insulin initiates the uptake of glucose by binding to the insulin receptore (1), this step
could lead to either of the four biological process; fatty acids metabolism-lipogenesis (6),
metabolism of pyruvate (5) glycogenesis (4) and import of glucose through the formation
of the glucose transporter-4 (3) leading to glycolysis.
(From, nutritionwonderland.com/2010/01/glucose-brain-alzheimers-diabetes)
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Figure 1.2 IRS system conveys insulin signaling
The Insulin and Insulin receptor play a key role in insulin signaling, after insulin binds to
the insulin receptor, a cascade of proteins including IRS1 & 2 participate in signaling the
synthesis of GLUT4 which is transported to the plasma membrane and stimulates glucose
transport. (Adapted from; Nelson D.L, Cox M.M (2001). Lerhninger Principles of
Biochemistry. New York, WH Freeman and company, 11(394-395)
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Rice et al showed that upon differentiation of 3T3-L1 fibroblasts into adipocytes,
expression of IRS-1 increases 10-20 fold and correlated with the onset of GLUT4 and
insulin receptor gene expression (Klitzman et al., 1993). Thus, IRS1 presents a prime
candidate for a proximal, obligate intermediate in the pathway mediating the metabolic
actions of insulin (see figure 1.2) (Gywn., 1997. and Klitzman et al., 1993). The
metabolic function of the second substrate IRS2 is yet to be clarified (Gwyn., 1997).
Nevertheless, results from several studies have the general agreement that IRS1 is
responsible for GLUT4 response to insulin.

The Glucose Transporter-1 (GLUT1)
GLUT1 has also been recently studied extensively (Wetheimer et al., 1991, and
Bruckner et al 1999). This transporter is expressed ubiquitously and is responsible for the
constitutive or basal level of glucose uptake (Wetheimer et al., 1991 and Louters et al.,
2006). Unlike GLUT4, GLUT1 is neither acutely responsive to insulin nor exercise. The
primary mode of regulation of this transporter is the induction of GLUT1 protein
synthesis by chronic exposure to cell stress (Wetheimer et al., 1991). For instance,
glucose deprivation for 12hr or more has been demonstrated to cause substantial
increases in GLUT1 content and activity in 3T3-L1 adipocytes (Klitzman et al., 1993). In
neural cells the combined effect of glucose deprivation and oxygen deprivation resulted
in increases in transport activity larger than 100-fold after 24h (Bruckner et al., 1999).
Chronic exposure to either hypoxia or oxidative phosphorylation inhibitors, such as
azide, also up-regulated GLUT1 expression in clone 9 cells (Behrooz et al., 1997).
However, in addition to this chronic or long-term control, there is evidence that GLUT1
is also under acute regulation. 30min starvation in L6 skeletal muscle cells stimulated
13

glucose uptake independent of protein synthesis (Mercado et al., 1989). Short term
exposure to cell stressors, such as hyperosmolarity and azide also stimulated the glucose
transport activity of GLUT1 in Clone 9 cells (Mercado et al., 1989). This acute activation
of GLUT1 increased the Vmax of transport without a change in the cell membrane
concentration of GLUT1 (Mercado et al., 1989). However, the location of the transporter
on the plasma membrane may change due to this acute activation (Barros et al., 2001).
Research has also demonstrated that the transport of glucose by GLUT1 obeys the
Michaelis- Menten kinetics (Palfreyman et al., 1992 and Fukumoto et al., 1989). The
transport of glucose is a facilitative process and is consistent with the alternating
conformation model (Gwyn., 1997). This model predicts a single substrate (glucose)
binding site, which is exposed either to the extracellular or intracellular space but not on
both sides simultaneously (Gwyn., 1997). Both sides, loaded or unloaded with glucose,
can re-orientate via a conformational change within the protein, so as to face the opposite
side of the plasma membrane (see figure 1.3). It should be noted that this mechanism can
be equally applied to substrate influx or eflux and is driven purely by the chemical
concentration gradient of glucose (Gwyn., 1997). The rate constants governing substrate
binding to GLUT1 can vary depending on which side of the membrane the transporter is
facing, which gives rise to an observed kinetic asymmetry. Furthermore, the rate
constants that govern the re-orientation of the empty GLUT1 are usually less than those
that govern the re-orientation of the loaded GLUT1, accounting for the phenomenon of
trans-acceleration (Gwyn., 1997).
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Figure 1.3. Alternate conformation mechanism of GLUT1
GLUT 1 in the (T1) state binds to glucose and changes conformation (T2) facing the
opposite side of the plasma membrane and releases the glucose thereafter returns to its
original conformation (T1) without undergoing any permanent irreversible structural
changes. (Adapted from; Nelson D.L, Cox M.M (2001). Lerhninger Principles of
Biochemistry. New York, WH Freeman and company, 11(392-393)
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MODEL SYSTEMS FOR THE STUDY OF GLUT1
In 1952, Widdas first theorized that sugar transport was a saturable, proteinmediated process using sheep blood-placental transport as his model system (Widdas.,
1952). Since then, erythrocytes have provided an ideal model system for the study of
GLUT1 kinetic properties: Red cells are readily available by donation, are uniform in size
and volume, may be lysed and resealed with desired contents, and GLUT1 is thought to
occupy 6% of the cell surface. Membrane-resident erythrocyte GLUT1 may be readily
purified for biochemical study. GLUT1 isolated from red cells is more heterogeneously
glycosylated than is observed in other tissues. While this impacts biochemical analysis, it
is not thought to affect functional behavior (Carruthers., 1990). Nonetheless, erythrocyte
GLUT1 provides a window into the kinetic properties of mammalian sugar flux.
The major disadvantage of erythrocyte GLUT1 is that it is not amenable to
mutagenic analysis. While clinical cases of GLUT1 deficiency syndrome have provided
some insight, they are resistant to systematic structural exploration. Some model systems
have been successfully employed to address this; Xenopus laevis oocytes and mammalian
cell lines such as 3T3L1 adipocytes, Chinese Hamster Ovary (CHO) cells, and Human
Embryonic Kidney Cells (HEK).

Xenopus Laevis
Mutant GLUT1 has been most commonly expressed via RNA injection in X.
laevis oocytes (Wellner, 1992). Oocytes, with their consistent size and volume, provide a
convenient vehicle for analysis of kinetic properties of mutant transporters by measuring
the transport of radiolabelled sugars. However, oocyte expressed GLUT1 is not
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uniformly gylcosylated, is not expressed at a sufficiently high density for purification,
and it does not self-associate into dimers and tetramers as observed in red cells (Zottola,
1995). This results in differing kinetic behavior from the human erythrocyte model,
notably the lack of reductant sensitivity (Levine et al, 2005). In other words, sugar uptake
into control erythrocytes without extracellular reductant (DTT-) is almost twofold greater
than erythrocytes treated with DTT (Zottola, 1995). Oocyte expressed GLUT1 is
unaffected by the presence of extracellular reductant (Levine et al, 2005).

Mammalian Cell Culture
Transient transfection of GLUT1 into Chinese Hamster Ovary (CHO) cells or
Human Embryonic Kidney 293T (HEK 293) cells have also proved a convenient vehicle
for studying the glucose fluxes of mutant GLUT1. Both cell types have a very low
concentration of endogenous glucose transporters, thereby facilitating heterologous
overexpression of mutant transporters. HEK 293 cells have the advantage that they retain
erythrocyte-like glycosylation patterns on the protein (Levine et al, 2005). Their
disadvantages lie in the cost of culture, and a lower protein density as compared to the
erythrocyte, rendering mutant protein purification a more expensive and complex
operation.
Furthermore, depending on the model system, to selectively measure the transport
activity of GLUT1 in vitro maybe a difficult task. This is because it has been shown by
immuno-precipitation using cell-surface transporter labeling that GLUT1 and GLUT4 are
80% present on the membrane of 3T3-L1 cells (Palfreyman et al., 1992). Consequently,
the presence of other transporters does not significantly contribute to total glucose uptake
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(Palfreyman et al., 1992 and Fukumoto et al., 1989). In addition, the kinetics of glucose
uptake that is modeled by the Michaelis-Menton equation is consequently the sum of the
transport activity of two isoforms, GLUT1 and GLUT4 (Palfreyman et al., 1992).
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PROPOSED STUDY
To avoid the confusion of measuring the transport activity of both isoforms
(GLUT1 and GLUT4) and other elements of the insulin signaling pathway such as IRS1
and IRS2, in order to understand the mechanism of berberine and HNO enhanced glucose
uptake activation, we will measure the effects of berberine and HNO in L929 fibroblast
cells, which only express GLUT1 and are non insulin responsive. Previous work has
shown that this transport can be rapidly activated through starvation (Tinball et al., 2006)
by a mechanism that has not yet been clarified.

Objectives of the Study
(a) The objective of this study is to investigate the effect of berberine and nitroxyl on the
transport activity of GLUT1 in L929 fibroblast cells: Does it increase or decrease the
Michaelis- Menton constant (Km) and maximum velocity (Vmax)?
(b) To obtain the dose and time dependent effects of berberine and nitroxyl (HNO) on
these cells.
(C) To obtain the recovery times of these cells from berberine and nitroxyl.
(d) To assay the effects of nitroxl on the structure of GLUT1, in order to understand the
mechanism of activation of glucose uptake by GLUT1 in these cells.
Furthermore, we will measure the effects of specific pathway inhibitors in order to gain
some insight into the mechanism of activation by berberine and nitroxyl. We will use the
results to determine if the effects of berberine and nitroxl on GLUT1 transport activity,
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might contribute to the improvement of glucose hemostasis in diabetic humans, upon
consumption of berberine and or, nitroxyl containing biopharceuticals.
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CHAPTER II
BERBERINE ACUTELY ACTIVATES THE GLUCOSE
TRANSPORT ACTIVITY OF GLUT1
This chapter was published July 2011 to the journal Biochimie (Elsevier) and can be
found using the following reference:
Alexandra Cok, Christina Plaisier, Matthew J. Salie, Daniel S. Oram, Jude Chenge, Larry
L. Louters, Berberine acutely activates the glucose transport activity of GLUT1,
Biochimie, Volume 93, Issue 7, July 2011, Pages 1187-1192, ISSN 0300-9084,
10.1016/j.biochi.2011.04.013.
(http://www.sciencedirect.com/science/article/pii/S0300908411001325)
Keywords: Berberine; Glucose uptake; GLUT1; ERK kinase; AMPK
Data presented in this chapter found in Tables 3.1 and 3.2, as well as Figures 3.1,3.2 and
3.4 were contributed to by myself, Jude Chenge; the remaining work was a collaboration
with Alexandra Cok, Christina Plaisier, Mathew Salie and Daniel Oram, Under
supervision by Larry Louters, Ph.D.
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ABSTRACT
Berberine, which has a long history of use in Chinese medicine, has recently been
shown to have efficacy in the treatment of diabetes. While the hypoglycemic effect of
berberine has been clearly documented in animal and cell line models, such as 3T3-L1
adipocytes and L6 myotube cells, the mechanism of action appears complex with data
implicating activation of the insulin signaling pathway as well as activation of the
exercise or AMP kinase-mediated pathway. There have been no reports of the acute
affects of berberine on the transport activity of the insulin-insensitive glucose transporter,
GLUT1. Therefore, we examined the acute effects of berberine on glucose uptake in
L929 fibroblast cells, a cell line that express only GLUT1. Berberine- activated glucose
uptake reaching maximum stimulation of five-fold at >40 μM. Significant activation (P <
0.05) was measured within 5 min reaching a maximum by 30 min. The berberine effect
was not additive to the maximal stimulation by other known stimulants, azide, methylene
blue or glucose deprivation, suggesting shared steps between berberine and these
stimulants. Berberine significantly reduced the Km of glucose uptake from 6.7 ± 1.9 mM
to 0.55 ± 0.08 mM, but had no effect on the Vmax of uptake. Compound C, an inhibitor
of AMP kinase, did not affect berberine-stimulated glucose uptake, but inhibitors of
downstream kinases partially blocked berberine stimulation. SB203580 (inhibitor of p38
MAP kinase) did not affect submaximal berberine activation, but did lower maximal
berberine stimulation by 26%, while PD98059 (inhibitor of ERK kinase) completely
blocked submaximal berberine activation and decreased the maximal stimulation by 55%.
It appears from this study that a portion of the hypoglycemic effects of berberine can be
attributed to its acute activation of the transport activity of GLUT1.
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INTRODUCTION
Berberine, an isoquinoline alkaloid isolated from several herbs including Rhizoma
Coptidis, has a long history of use in Chinese medicine for the treatment of
gastrointestinal infections, diarrhea, cardiovascular diseases, inflammation and
hypercholesterolemia (Yin et al., 2008 and Lau et al., 2001). More recently, berberine
has been also proven to be efficacious for the treatment of type-2 diabetes (Yin et al.
2008; Ni et al., 1988 and 1994). Studies using human patients (Yin et al. 2008; Ni et al.
1988; 1994 and Lee et al., 2006), animal or cell models of insulin resistance (Lee et al.,
2006; Yin et al., 2008; Yi et al., 2008; Chen et al., 2009; Zhang et al., 2008; Leng et al.,
2004 and Gao et al., 1997), or insulin sensitive cell lines (Liu et al., 2010; Cheng et al.,
2006; Kim et al., 2007 and Zhou et al., 2007) that have all established a clear
hypoglycemic effect of berberine.
In general, there are two distinct pathways to activate glucose uptake in peripheral
tissues; one stimulated by insulin through the IRS-1/PI 3-kinase and the other by exercise
or hypoxia via activation of AMPK as shown in figure 1.2. In muscle, which is the
major tissue responsible for whole body glucose disposal, both pathways stimulate the
translocation of GLUT4 to the cell membrane, which accounts for the enhanced glucose
uptake (Krook et al., 2004). Current data suggests that the effects of berberine are
complex and may activate portions of both insulin and exercise-induced glucose uptake
pathways (Liu et al., 2010 and Kim et al., 2007). In addition, berberine inhibits intestinal
absorption of glucose that also contributes to berberine’s hypoglycemic effect (Pan et al.,
2003).
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The effects of berberine on the insulin stimulated glucose uptake pathway are
varied and sometimes conflicting (Yin et al., 2008 and Liu et al., 2010), which can be, in
part, attributed to the variety of cell types and treatment times utilized in these studies.
However, there appears to be a general agreement from multiple studies that berberine
activates AMPK (Lee et al., 2006, Yin et al., 2008, Liu et al., 2010, Cheng et al., 2006,
Kim et al., 2007 and Zhou et al., 2007, and Brusq et al., 2006). These studies have been
done in insulin sensitive cells where a change in glucose transport is typically attributed
to a change in GLUT4 activity. Some studies have specifically implicated GLUT1 as the
primary transporter responsible for the enhanced glucose uptake, but these studies
investigated the chronic effects of berberine (6 -12 hour treatments) (Kim et al and Zhou
et al., 2007). The acute or short-term effects of berberine on GLUT1 activity uptake have
not been studied.
There is increasing evidence that the more widely expressed GLUT1, initially
thought to be only responsible for basal glucose uptake, can be acutely activated by cell
stressors such as azide (Shetty et al., 1993 and Rubin., 2003), osmotic stress (Barnes et
al., 2002 and Barros et al., 2001), methylene blue (Louters et al., 2006), and glucose
deprivation (Kumar et al., 2004 and Roelofs et al., 2006). In addition, it has been
recently shown that peptide C activates GLUT1 transport activity in erthryocytes,
establishing a potential link between GLUT1 activity and diabetes (Meyer et al., 2008).
In particular, the acute activation of GLUT1 by hypoxia or azide has been attributed to an
activation of AMPK (Barnes et al., 2002; Jing et al., 2007, 2008). Therefore, the
specific purpose of this study was to systematically investigate the acute effects of
berberine on glucose uptake in L929 fibroblast cells, a cell line that expresses only

24

GLUT1 (Liong et al., 1999) and has been shown to respond to acute cell stress by
increasing glucose uptake (Louters et al and Roelofs et al., 2006).
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RESULTS

Berberine Activates Glucose Uptake in a Dose Dependent Manner
A six-hour berberine treatment increased GLUT1 expression and subsequent
glucose uptake in 3T3-L1 cells (Kim et al., 2007). However, the acute effects of
berberine on the activity of this transporter have not been measured. To investigate the
acute effects of berberine on basal glucose uptake by GLUT1, L929 fibroblast cells were
exposed to DMEM media containing 5.5 mM glucose and increasing concentrations of
berberine for 30 minutes. The results, shown in Figure 2.1, show a dose dependent
stimulation of glucose uptake that reached a maximum 5-fold stimulation at 100µM
berberine. There was a statistical activation of uptake at 10 µM (1.55x) and uptakes at
concentrations greater than 40 µM were not different from each other. Therefore in
subsequent experiments, concentrations >40 µM berberine were considered to be
maximally effective.
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Figure 2.1. Effects of berberine on 2DG uptake.
L929 fibroblast cells were incubated at 37 °C for 30 min in DMEM media (5.5
mM glucose) supplemented with 0-100 mM berberine as indicated. Ten-minute 2DG
uptakes were then measured as described in Materials and methods. Data are means± S.E.
of normalized values from multiple experi- ments (samples size varied from 3-20). a
significantly different than 0 mM berberine and bsignificantly different than 100 mM
berberine at P < 0.01.
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Time Course of Activation and Recovery of Berberine Activated Glucose
Uptake
To measure the effects of time, L929 cells were incubated in DMEM media (5.5
mM glucose) containing berberine for times ranging from 5-60 minutes. The results
shown in Figure 2.2 indicate that a statistically activation was achieved within 5 minutes
(from 1.79±0.09 to 2.97±0.18 nmol/10 min/well) and maximized by 30 minutes
(4.97±0.17 nmol/10 min/well). The 0, 30, and 60 minute time points were also done in
the presence of cyclohexamide , which had no effect on glucose uptake (data not shown).
This indicates that the activation of glucose uptake by berberine is not dependent on
protein synthesis.
In a separate experiment recovery from the effects of berberine were measured by
exposing cells to berberine for 30 minutes, followed by a wash and resuspension in media
lacking berberine for various times up to 60 minutes. As shown in Figure 2.3, the effects
of berberine were largely maintained for a full 30 minutes post exposure (86.9%), and
50.7% of the activity remained after 60 minutes.
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Figure 2.2. Effect of time of berberine exposure on 2DG uptake.
L929 fibroblast cells were incubated at 37 °C for 30 min in DMEM media (5.5 mM
glucose) supplemented with 40 mM berberine for 0, 5, 10, 30, 45, and 60 min. Tenminute 2DG uptakes were then measured as described in Materials and methods. Data are
means ±S.E. of a representative experiment. aSignificantly different than 0 min exposure
to berberine and bsignificantly different than 1 h at P < 0.01.
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Figure 2.3. Effect of recovery time on berberine-activated 2DG uptake.
L929 fibroblast cells were incubated at 37 °C for 30 min in 5.5 mM glucose DMEM
media supplemented with 40 mM berberine. Samples were washed and re-suspended in
media without berberine for 0-60 min. Ten-minute 2DG uptakes were then measured as
described in Materials and methods. Data are means ±S.E. of a representative experiment.
2DG uptake rates at all recovery times are statistically different from the control (0 min)
at P < 0.05.
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Additive and Kinetics Effects Of Berberine Activation
In order to gain some insight into to the activation pathway of berberine, we
conducted a series of additivity experiments as well as investigated the kinetics of the
berberine effect. We had previously shown that glucose uptake in L929 fibroblast cells
can be acutely activated by multiple agents including nitric oxide, troglitazone, azide,
methylene blue and glucose deprivation (Louters et al., 2006; Roelofs et al., 2006 and
Van Dyke et al., 2003). In particular, acute activations by methylene blue and glucose
deprivation were shown to be additive with different kinetic effects, suggesting that there
is a least two distinct activation mechanisms of glucose uptake in L929 cells (Louters et
al., 2006 and Roelofs et al., 2006).
L929 cells were exposed to maximally effective concentrations of either sodium azide (5
mM), methylene blue (50 µM), berberine (50 µM), or media lacking glucose for 30
minutes. Glucose uptake measurements are shown on Table 2.1 and as can be seen, each
stimulant significantly activated glucose uptake. Additionally, other cells were exposed
to a combination of maximally effective concentrations of berberine plus azide, or
methylene blue, or glucose deprivation. As seen on Table 2.1, the effects of berberine
were not additive to any of the stimulants, suggesting that berberine shares significant
portions of the activation pathways with of all these stimulants.
The kinetics of glucose uptake were measured in the presence and absence of berberine
and the results are shown on Figure 2.4. An best fit analysis of the data using MichaelisMenton kinetics indicates that berberine does not affect the Vmax (both between 13-14
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nmol/10 min/well) but dramatically lowers the Km of uptake from about 5.5 mM to 0.7
mM.
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Table 2.1. Combined effects of various stimulants of glucose uptake
[Berberine]

Controls

+ Azide

+ MB

+No glucose

0 µM

1.00 0.04

1.79 0.09

2.54 0.10

2.87 0.36

50 µM

3.17 0.10

3.23 0.18

3.37 0.18

3.04 0.40

L929 fibroblast cells were incubated for 30 minutes at 37

in DMEM media (5.5 mM

glucose or 0 mM glucose) containing either 0 or 50 µM berberine alone or in
combination with either 5.0 mM sodium azide, or 50 µM methylene blue. Glucose
uptake was measured as described in Materials and Methods and normalized to control
with no berberine. All uptakes are statistically higher than the control at P<.01, but all
uptakes with 50 µM berberine were not different.
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Figure 2.4. Kinetics of 2DG uptake in control and berberine-activated cells.
L929 fibroblast cells were incubated at 37 °C for 30 min in DMEM media (5.5 mM
glucose) supple- mented with either 0 or 80 mM berberine. Ten-minute 2DG uptakes
were then measured at varying concentrations of 2DG (0.1, 0.5, 1, 5, 10, or 20 mM). Data
are means ±S.E. of a representative experiment.
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Effects of Inhibitors on Berberine Activated Glucose Uptake
Multiple studies have suggested that berberine activates AMPK (Lee et al., 2006,
Yin et al., 2008; Liu et al., 2010, Cheng et al., 2006; Kim et al., 2007, Zhou et al., 2007
and Brusq et al., 2006). To explore this possibility, we pretreated cells with 0, 10, 20, or
50 µM compound C, an inhibitor of AMPK, for 45 minutes, followed by a 30 minute
exposure to 50 µM berberine in the continued presence of compound C. The results,
shown in Figure 2.5, again demonstrate a robust activation of glucose uptake from
2.39±0.17 to 7.74±0.36 nmol/10min/well, which was not altered by the pretreatment with
compound C.
We also measured the effects of pretreatment of wortmannin (inhibitor of PI3K),
SB203580 (inhibitor of p38 kinase), and PD98059 (inhibitor of ERK). As expected and
previously shown (Kim et al., 2007), wortmannin had no effect on either basal or
berberine stimulated glucose uptake (data not shown). However, both SB203580 and
PD98059 partially inhibited berberine stimulated glucose uptake. We pretreated cells
with effective concentrations of either the p38 kinase inhibitor (10 µM SB203580) or the
ERK inhibitor (50 µM PD98059) (Kim et al., 2007) followed by either a submaximum
(10 µM) or maximum (50 µM) berberine activation in the continued presence of the
inhibitor. As shown on Table 2.2, treatment with either inhibitor alone did not
significantly altered basal glucose uptake. SB203580 did not affect submaximum
berberine activation but did lower maximum berberine stimulation by 26% (decrease
from 4.13 ± 0.17 to 3.31 ± 0.09 nmol/10min/well). In contrast PD98059 was a much
more effective inhibitor. It completely blocked submax berberine activation and
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decreased the maximum stimulation by 55% (decrease from 4.13 ± 0.17 to 2.41 ± 0.05
nmol/10min/well).
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Figure
2.5. Effect of Compound C on berberine-activated 2DG uptake.
L929 fibroblast cells were pretreated for 45 min at 37 °C in DMEM media (5.5 mM
glucose) supplemented with 0, 10, 20, or 50 mM compound C, then incubated for 30 min
in 5.5 mM glucose DMEM media still supplemented with compound C and either 0 or 50
mM berberine. Ten-minute 2DG uptakes were then measured as described in Materials
and methods. Data are means ±S.E. of a representative experiment.
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Table 2.2. Effects of inhibitors on berberine activated glucose uptake
[Inhibitor]

[Berberine]

SB203580

PD98059

0 µM

10 µM

0 µM

0 µM

1.00

0.03

1.44

0.08

4.13

0.17

10 µM

0 µM

0.91

0.02

1.46

0.03

3.31

0.09*

0 µM

50 µM

0.91

0.10

1.06

0.08*

2.41

0.05#

As controls, cells were incubated for 30 minutes at 37

50 µM

in DMEM media containing

either 0 (basal), 10 µM (submax stimulation), or 50 µM (max stimulation). The
inhibitors, SB203580 (at 10 µM) and PD98059 (at 50 µM) were incubated with cells for
45 minutes prior to a 30 minute incubation with either 0, 10, 50 µM berberine plus the
inhibitor. Glucose uptake was measured as described in Materials and Methods and
normalized to control with no berberine and no inhibitor. Significant effects of the
inhibitor compare to its berberine control were at P<.05 (*) and P<.01 (#).
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DISCUSSION

Berberine, an isoquinoline alkaloid isolated from a number of plants, has a rich
history of use in Chinese medicine. It seems clear, considering the wide spectrum of
therapeutic applications such as treatments for parasitic infection, bacterial diarrhea,
inflammation, cardiovascular disease, hypercholesteremia, and diabetes, that berberine
must trigger a number of physiological responses in biological systems.
Recent studies have documented berberine’s effectiveness in the treatment of both
human diabetes patients (Yin et al., 2008 and Ni et al., 1988 & 1994) and animal models
of diabetes (Lee et al., 2006; Zhang et al., 2008; Leng et al., 2004 and Gao et al 1997).
This has lead to numerous studies designed to understand berberine’s mechanism of
action regarding its hypoglycemic effect. The results of these studies are somewhat
confusing and sometimes conflicting. Some studies indicate that berberine works
through the insulin pathway by enhancing either insulin secretion (Leng et al., 2004) or
the signaling cascade (Yi et al., 2008; Chen et al., 2009; Wang et al., 2012; Zhang et al
2010; Ko et al., 2005 and Chen et al., 2010). Others suggest berberine stimulates AMPK
in an insulin pathway-independent fashion (Lee et al., 2006, Cheng et al., 2006; Kim et al
2007; Zhou et al., 2007; and Turner et al., 2008) while others suggest that berberine has
effects on both pathways (Yin et al., 2008 and Liu et al., 2010). In most studies the
berberine-enhanced glucose uptake has been attributed to increased GLUT4 activity.
Some studies indicated that berberine increases GLUT4 production (Prabhakar et al.,
2009) or translocation (Lee et al., 2006; Ko et al., 2005 and Prabhakar et al., 2009),
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however other studies were unable to detect changes in GLUT4 (Kim et al., 2007 and
Wang et al., 2008).
The acute effects of berberine on the transport activity of GLUT1 remain largely
unexplored. A study in 3T3-L1 adipocytes showed that a 6 hour exposure to berberine
increases GLUT1 synthesis with no change in GLUT4 (Kim et al., 2007) however a
second study reported that a 24 hour exposure to berberine did not change either GLUT1
or GLUT4 content and suggested in their conclusions that berberine increases GLUT1
activity, (Zhou et al., 2007). To explore the effects of berberine on GLUT1 activity, we
measured glucose uptake in the presence of berberine in L929 fibroblast cells, a cell line
that only expresses GLUT1 (Liong et al., 1999). We report that berberine significantly
activates glucose transport at 10 µM and reaches a maximum stimulation of about 5-fold
at concentrations above 40 µM (see Figure 2.1). A significant activation occurs within 5
minutes and this acute effect platues at about 30 minutes. This activation was also not
sensitive to cyclohexamide indicating that this berberine effect does not depend on new
protein synthesis.
Recovery from berberine activation is slower than the activation with about 90%
of the acti- vation remaining after 30 min and 50% after 60 min.
Previous studies have suggested two distinct mechanisms for the activation of
glucose uptake in L929 cells, one mechanism illustrated by the effects of methylene blue
or sodium azide and the other by glucose deprivation (Louters et al., 2006 and Roelofs et
al., 2006). The kinetic analysis of the berberine activation indicates that the Km of
glucose transport is decreased, but the Vmax is unaffected, suggesting that sensitivity of
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the system is enhanced, but not the responsiveness. This kinetic behavior is similar to that
observed upon glucose deprivation in this cell line (Roelofs et al., 2006). To further
explore the mechanism of berberine- activated glucose uptake we explored the additivity
of berberine’s effects with maximally effective concentrations of methylene blue and
azide or glucose deprivation. The results (Table 2.1) indicate that among these
stimulants, berberine induces the most robust activation of glucose uptake and that its
effects are not enhanced by the other stimulants. This suggests that the mechanism of
berberine activation shares common steps with both pathways.
Key studies in other cell lines have strongly suggested that berberine activation of
glucose uptake is mediated through activation of AMPK. To explore this possibility we
measured the dose dependent effects of Compound C, an inhibitor of AMPK, on both
basal and berberine-stimulated glucose uptake. Compound C had no effect on glucose
uptake, suggesting AMPK is not involve in the stimulation of glucose uptake in L929
cells. This is consistent with previous work in L929 cells that reported that AICAR, an
activator of AMPK, inhibited rather than activated glucose uptake (Louters et al., 2006).
This result was somewhat surprising given that previous work in L6 myotube cells had
shown that the activation of glucose uptake by berberine could be completely blocked by
compound C (Cheng et al., 2006). We were able to repeat those results with L6 myotube
cells in our laboratory as well (data not shown) suggesting that AMPK is not involved in
the activation of glucose uptake in L929 cells. Also, since L6 myotube cells express both
GLUT1 and GLUT4, this may suggest that AMPK activation is required for the
activation of GLUT4, but not for GLUT1. The lack of involvement of AMPK in
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regulating glucose uptake in L929 fibroblast cells indicate that additional studies need to
be done investigate the expression levels and role of AMPK in this cell line.
Studies that support AMPK activation as a key step in berberine’s effects are not
all in agreement regarding which downstream kinases are involved. Some studies
implicate activation of ERK kinase (Zhou et al., 2007 and Kim et al., 2007), while others
provide evidence of berberine’s activation of p38 MAPK (Lee et al., 2006 and Louters et
al., 2006). To investigate the involvement of these two kinases we measured the effects
of SB203580 (inhibitor of p38 MAPK), and PD98059 (inhibitor of ERK kinase) on
berberine- stimulated glucose uptake. SB203580 had no effect on sub- maximally
effective concentrations of berberine, but reduced maximum stimulation by 26%, while
PD98059 completely blocked submaximal berberine stimulation and reduced maximum
stimulation by 55%. The combination of the two inhibitors did not further inhibit
berberine stimulation of glucose uptake (data not shown). These data suggest that ERK
kinase pathway may be more involved than p38 MAPK, but neither is able to account for
the full stimulatory effect of berberine. It is important to note that these inhibitory studies
should be considered to be just the initial steps in discerning the mechanism of berberine
activation of GLUT1. One concern is a potential cross reactivity of the inhibitors. For
example, recent work in striated muscle has demonstrated that SB203580 also
significantly inhibits the activation of Akt, a serine/threonine protein kinase, activated in
the insulin signaling system (Kim et al., 2006). While this may not be important in L929
fibroblast cells, since this cell line is not insulin sensitive, it does point to potential
complications in interpreting the results. Thus, future studies should look for a berberine
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stimulation of the phosphorylation of these kinases as well as identify other factors to
account for the full activation of berberine.

CONCLUSSION
This study demonstrates for the first time that berberine acutely activates the transport
activity of GLUT1. In addition, the mecha- nism of activation is complex, but likely
involves, in part, the acti- vation of ERK kinase and to a lesser degree p38 MAPK. The
activation of these kinases in L929 cells appears to occur without the activation of
AMPK. Thus it is likely, that a portion of the hypoglycemic activity of berberine, that has
been observed by others, can be attributed to its acute activation of the transport activity
of GLUT1. GLUT1 is widely expressed and is the unique transporter responsible for
glucose uptake into the central nervous system. Thus, the ability of berberine to acutely
up regulate the activity this transporter may suggest a useful strategy to help counter the
damaging effects of strokes caused by arterial blockage as well as damage to
cardiomycytes that occurs during a cardiac infarction.
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CHAPTER III
NITROXYL (HNO) ACUTELY ACTIVATES THE GLUCOSE
UPTAKE ACTIVITY OF GLUT1
This chapter was published March of 2012 to the journal Biochimie (Elsevier) and can be
found using the following reference:
Matthew J. Salie, Daniel S. Oram, David P. Kuipers, Jared P. Scripture, Jude Chenge,
Griffin J. MacDonald, Larry L. Louters, Nitroxyl (HNO) acutely activates the glucose
uptake activity of GLUT1, Biochimie, Volume 94, Issue 3, March 2012, Pages 864-869,
ISSN 0300-9084, 10.1016/j.biochi.2011.12.005.
(http://www.sciencedirect.com/science/article/pii/S0300908411004603)
Keywords: Angeli’s salt; Nitroxyl (HNO); GLUT1; Glucose uptake; L929 fibroblast cells
Data presented in this chapter found in Table 3.1, as well as Figures 3.1,3.2 and 3.6 were
contributed to by myself, Jude Chenge; the remaining work was a collaboration with
Mathew Salie, Daniel Oram, Davis Kuipers, Jared Scripture and Griffin Macdonalds,
under supervision by Larry Louters, Ph.D.
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ABSTRACT
Nitroxyl (HNO) is a molecule of significant interest due to its unique
pharmacological properties, particularly within the cardiovascular system. A large
portion of HNO biological effects can be attributed to its reactivity with protein thiols,
where it can generate disulfide bonds. Evidence from studies in erythrocytes suggests that
the activity of GLUT1 is enhanced by the formation of an internal disulfide bond.
However, there are no reports that document the effects of HNO on glucose uptake.
Therefore, we examined the acute effects of Angeli’s salt (AS), a HNO donor, on glucose
uptake activity of GLUT1 in L929 fibroblast cells. We report that AS stimulates glucose
uptake with a maximum effective concentration of 5.0 mM. An initial 7.2-fold increase
occurs within 2 min, which decreases and plateaus to a 4.0-fold activation after 10 min.
About 60% of the 4.0-fold activation recovers within 10 min, and 40% remains after an
hour. The activation is blocked by the pretreatment of cells with thiol-reactive
compounds, iodoacetamide (0.75 mM), cinnamaldehyde (2.0 mM), and phenylarsine
oxide (10 μM). The effects of AS are not additive to the stimulatory effects of other acute
activators of glucose uptake in L929 cells, such as azide (5 mM), berberine (50 μM), or
glucose deprivation. These data suggest that GLUT1 is acutely activated in L929 cells by
the formation of a disulfide bond, likely within GLUT1 itself.
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INTRODUCTION
The biological effects of nitroxyl (HNO) are significantly different from nitric
oxide (NO) and its distinctive properties and potential to be a cell-signaling molecule are
receiving increasing attention (Fukuto et al., 2009& 2011, Irvine et al., 2008, Switzer et
al., 2009 and Paolocci et al., 2007). In particular, HNO has documented efficacy for the
treatment of heart failure (Dai et al., 2007, Feelisch et al 2003, Froehlich et al 2008,
Paolocci et al., 2001 and Tocchetti et al., 2007) and alcoholism (DeMaster et al., 1998).
The physiological effects of HNO appear to be mediated by its reactions with
hemeproteins and with thiols (Fukuto et al., 2009 & 2011, Kumar et al., 2010, and Miller
et al., 2009). In particular, the unique reaction of HNO with biological thiols is well
established. It can react with one thiol to produce a sulfinamide as the endproduct, which
often inhibits the protein. For example, HNO inhibits aldehyde dehydrogenase (DeMaster
et al., 1998, and Shoeman et al., 2000) accounting for its use for treatment of alcoholism,
glyceraldehyde-3-phosphate dehydrogenase (Lopez et al., 2005 & 2007) accounting for
its toxicity in yeast, papain (Vaananen et al., 2005 & 2008), and cathepsin B (Vaananen
et al., 2008). In contrast, HNO can react with two thiols to produce a reversible disulfide
end product plus hydroxylamine. This appears to account, in part, for the positive effects
of HNO on cardiac muscle contractility. HNO has been shown to react with several
sarcoplasmic proteins involved in Ca2+ release and uptake, including the ryanodine
receptor (Cheong et al 2005), Ca2+-ATPase (SERCA) (Tocchetti et al., 2007) and
phospholamban (Froehlich et al., 2008), a protein that regulates SERCA. It is not clear,
at this time, if HNO is produced by cells as a physiological signal or if it is purely a
pharmacological agent (Fukuto et al., 2011).
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Long thought to be responsible only for basal glucose uptake, there is mounting
evidence that the ubiquitously expressed GLUT1 can be acutely activated. Cell stressors
such as azide (Shetty et al., 1993 and Rubin et al., 2003), osmotic stress (Barnes et al.,
2002 and Barros et al., 2001), methylene blue (Louters et al., 2006), C-peptide (Meyer et
al., 2008) and glucose deprivation (Kumar et al., 2004 and Roelofs et al., 2006) all
increase the transport activity of GLUT1. In contrast to GLUT4 activation, the activation
of GLUT 1 occurs without a change the membrane concentration of the transporter.
Currently it is not clear what alteration in GLUT1 structure accounts for its enhanced
activity. One possible mechanism proposed by the Curruthers lab (Graybill et al., 2006,
Carruthers et al., 2009; Zottola et al., 1995; Hebert et al., 1992 and Pessino et al., 1991)
and based on their work with erythrocytes suggests that GLUT1 is activated by the
formation of an internal disulfide bond. This triggers a conformational change in GLUT1
and leads the oligomerization (tetramer) and activation of the transporter. In support of
this possible mechanism, we have found that two thiol active agents, phenylarsine oxide
(Scott et al., 2009) and cinnamaldehyde (Plaisier et al., 2011), both activate glucose
uptake in L929 fibroblast cells, a cell line that express only the GLUT1 isoform (Liong et
al., 1999). Based on the Curruthers mechanism, we would predict that HNO would
trigger a disulfide bond formation in GLUT1, which appears to be the preferred HNOinduced product in a hydrophobic environment (Sherman et al., 2010), and thereby
activate glucose uptake. Therefore, the specific purpose of this study was to
systematically investigate the acute effects of Angeli’s salt (AS), an in situ producer of
HNO, on glucose uptake in L929 fibroblast cells.
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RESULTS
Angeli’s Salt Activates Glucose Uptake in a Dose Dependent Manner.
Data from erythrocytes suggests that GLUT1 can be activated by an internal
disulfide bond formation, which leads to an oligomerization of the transporter (Herbert et
al., 1992 and Pessino et al., 1991). Since AS stimulates disulfide bond formation via an
in situ release of HNO (Fukuto et al., 2009 & 2011), we were curious to understand if AS
could activate glucose uptake in L929 fibroblast cells, cells, which express only GLUT1
(Liong et al., 1999). In our initial experiment, L929 fibroblast cells were exposed to 10
mM Angeli’s salt either only during a 30-minute treatment phase, or during both the
treatment and a 10-minute uptake phase, or only during the uptake phase. We choose this
concentration because previous work had shown that AS in the range of 0.25-10 mM
stimulated the dimerization of the cardiac sacroplasmic reticulum protein,
phospholamban (Froelich et al., 2008). The results, shown in Figure 3.1, reveal that the
greatest activation is observed when AS is included only during the uptake phase (uptake
increased 4.2x from 1.01±0.03 to 4.21±0.14 nmol/10 min/well). In a subsequent
experiment, the dose dependency of glucose uptake was determined by exposing cells
only during the 10-minute uptake to a concentration of AS ranging from 0-20 mM. The
results are shown in Figure 3.2. There was a significant activation of uptake (P<0.01) at
1.0 mM (2.5x from 0.38±0.03 to 0.97±0.05 nmol/10 min/well), which maximized at 5.0
mM (uptake increased 3.8x from 0.38±0.03 to 1.46±0.14 nmol/10 min/well). There was
a small, but significant decrease to 1.04±0.05 nmol/10 min/well in the activation at 20
mM AS. AS did not produce any visible toxic effects, as assessed by cell morphology
and cell attachment, at any concentration tested.
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Figure 3.1. Effects of AS on 2DG uptake.
L929 fibroblast cells were incubated at 37 °C for 30 minutes in DMEM media (5.5 mM
glucose) supplemented with or without 10.0 mM AS. Ten-minute 2DG uptakes were
then measured as described in Materials and Methods in the presence and absence of 10
mM AS. Con (control) represent cells not exposed to AS, (Tr) represent cells exposed to
AS during the 30-minute treatment phase, (Tr+Up) were cells treated to AS during both
the treatment and uptake phase, and (Up) were cells exposed to AS only during the 10minute uptake phase. Data are means ± S.E. All uptakes in AS-treated cells are
significantly elevated at P<0.01.
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Figure 3.2. Dose dependent effects of AS on 2DG uptake.
Ten-minute 2DG uptakes were measured in the presence of AS concentrations ranging
from 0-20 mM as described in Materials and Methods. Data are means ± S.E. of a
representative experiment. aSignificantly different than 0 mM exposure to AS and
b

significantly different than 5.0 mM AS at P<0.01.
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Control Experiments
AS decomposes with a half-life of about 2.5 minutes to release HNO and nitrite
(Irvine et al., 2008). HNO itself is not stable for long term, but undergoes a selfdimerization reaction to produce nitrous oxide (N2O) plus water (Fukuto and Carrington
2011). To insure that the activity we were observing was a result of HNO and not nitrite,
we compared the effects of AS when is was added to uptake just before the measurement
of uptake to the effects when AS was added to the uptake media and incubated at room
temperature overnight. The results, normalized to control, are shown in Figure 3.3. The
overnight incubation did reduce uptake from 3.04±0.01 times control to 2.19±0.06, but it
remained significantly elevated. The activity could not be attributed to nitrite, because 5
mM nitrite had no effect of glucose uptake (see Figure 3.3). It may be that HNO
dimerization is slow enough such that significant nitroxl remains after the overnight
incubation. To test this, we incubated the 5.0 mM AS uptake media overnight in the
presence of excess thiol (10.0 mM cysteine). As seen in Figure 3.3, this mixture no
longer activated glucose uptake. In addition, cysteine by itself had no effect on glucose
uptake.
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Figure 3.3. Control experiments.
2DG uptakes were measured as described in Materials and Methods in the presence of
5.0 mM AS added just before uptake (AS), 5.0 mM AS allowed to decompose overnight
at room temperature (dAS), 5.0 mM sodium nitrite (Nit), 5.0 mM AS plus 10.0 mM
cysteine incubated overnight, or 10.0 mM cysteine. Both AS and dAS were (*)
significantly elevated at P<0.01.
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Time Course of Activation and Recovery of AS-activated Glucose Uptake
It seems possible that the much lower activation observed when AS was placed
only in the 30-minute treatment phase (see Figure 3.1) could actually represent activation
followed by a recovery as HNO is depleted. Therefore, to explore time course of
activation, L929 cells were exposed to 5 mM AS in the radioactive uptake buffer for
times ranging from 2-20 minutes. The results, expressed as nmols per minute, are shown
in Figure 3.4. The zero time represents the uptake per minute for control cells that had
been exposed to uptake media for 20 minutes without AS. The data shows a burst of
activation in the first three minutes followed by a steady rate of uptake that remains
elevated (4.0x) over control for the remainder of the 20 minutes. This burst of activity
correlates nicely with the half-life for the release of HNO from AS.
To measure the recovery from the effects of AS, L929 cells were to AS for 10
minutes, then resuspended in DMEM media (5.5 mM glucose) without AS and uptakes
were measured either immediately or after 5, 10, 25 and 50 minutes. As shown in Figure
3.5, about 60% of the activity recovered within 10 minutes, but about 40% remained even
after 50 minutes. This experiment was repeated multiple times and all results revealed a
fast recovery phase lasting between 5-10 minutes with a residual activation of 20-50%
that remained after an hour.
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Figure 3.4. Time course for AS-activation of 2DG uptake.
2DG uptakes in the presence of 5.0 mM AS were measured for 2, 3, 5, 8, 10, 15, and 20
min as described in materials and methods and expressed as the average nmol
2DG/minute ` S.E from four wells of a representative experiment. The uptake at 0 min
exposed to AS represents the per minute-uptake for a 20-min uptake for cells not exposed
to AS. aSignificantly different than zero time exposure to AS and bsignificantly different
than maximum effect at 2 min exposure to AS at P < 0.01.
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Figure 3.5. Effect of recovery time on AS-activated 2DG uptake.
L929 fibroblast cells were incubated at 37 C for 10 min in DMEM media (5.5 mM
glucose) supplemented with 5.0 mM AS. Ten-minute 2DG uptakes were then measured
immediately or media were replaced with AS-free media and uptakes were measured
after 5, 10, 25, or 50 min. Data are expressed as a percentage of full activation (0 min
recovery) ` S.E. from three wells of a representative experiment. aSignificantly different
than basal uptake (0% activation) and bsignificantly different than 100% activation at P <
0.01.
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Effects of Pretreatment with Thiol-reactive Compounds on AS Activation
If the activation of glucose uptake by AS is triggered by a reaction of HNO with
thiols, we ought to be able to inhibit the activation by pretreating the cell with a thiol
reactive compound. To test this, we pretreated L929 cells with 0.75 mM iodoacetamide
for 20 minutes before activation with AS. The results are shown in Figure 3.6.
Pretreatment with iodoacetamide by itself did not affect glucose uptake (0.97 ± 0.02
compared to 0.90 ± 0.04 nmol/10 min/well for control), but essentially completely
inhibited activation by AS (reduced uptake from 3.78 ± 0.07 to 1.3 ± 0.05 nmol/10
min/well). When a stock iodoacetamide was incubated overnight (room temperature)
with an equal concentration of cysteine, the iodoacetamide no longer inhibited ASactivation of glucose uptake. Cysteine itself did not alter glucose uptake (see Figure 3.3).
We also investigated the effects of two other thiol-reactive compounds,
cinnamaldehyde (CA) and phenylarsine oxide (PAO). Previous work had shown that
these two agents can activate glucose uptake in L929 cells, but they also inhibit
subsequent activation by more robust activators of glucose uptake (Scott et al., 2009 and
Plaisier et al., 2011). We treated cells with either 2 mM CA or 10 µM PAO for 30
minutes and then measure glucose uptake in the presence and absence of 5 mM AS. The
results are shown on Table 3.1. As previously reported, treatment with either CA or
PAO activated glucose uptake (Scott et al., 2009 and Plaisier et al., 2011), but not to the
same degree as AS. However, treatment with CA or PAO prior to treatment with AS
blocked the activating effects of AS.
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Figure 3.6. Effect of iodoacetamide on AS-activated 2DG uptake. L929 fibroblast cells
were treated for 20 min at 37 C in DMEM media (5.5 mM glucose) alone or
supplemented with 0.75 mM iodoacetamide or supplemented with a mixture of 0.75 mM
iodoace- tamide and 0.75 mM cysteine that had been incubated overnight. Ten-minute
2DG uptakes were then measured in the presence and absence of 5 mM AS. (Con) represents control cells not treated with iodoacetamide or AS, (I) represents cells exposed to
iodoacetamide during the 20-min treatment, (AS) represents cells exposed to AS during
the 10-min uptake, (I + AS) represents cells pre-treated with iodoacetamide and exposed
to AS during the uptake phase, and ((I + C)+AS) represents cells pre- treated with an
iodoacetamideecysteine mixture and then exposed to AS. Data are means ` S.E. from four
wells of a representative experiment. *Significantly elevated from control at P < 0.01.
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Table 3.1 Effects of CA- and PAO-treatment on AS-activation of glucose uptake
Treatment

2DG uptake (w/o AS )
(nmol/10 min/well)

2DG uptake (+ 5.0 mM AS)
(nmol/10 min/well)

Control

1.410.03

2.840.08

2.0 mM CA

1.990.07*

1.510.15*

10.0 µM PAO

2.170.06*

2.090.09#

L929 fibroblast cells were incubated for 30 minutes at 37 in DMEM media (5.5 mM
glucose or 0 mM glucose) plus either no additions (control), 2.0 mM CA or 10.0 µM
PAO. Glucose uptake was measured as described in Materials and Methods in the
presence and absence of 5.0 mM AS. Significance from respective control at P<.01 (*),
or at P<.05 (#).
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Combined Effects of Activators on Glucose Uptake
We had previously shown in L929 fibroblast cells that glucose uptake can be
acutely activated by multiple agents (Louters et al., 2006 and Roelofs et al., 2006). In
order to gain some insight into to the activation pathway of AS, we conducted a series of
additivity experiments with three of these activators, azide, berberine and glucose
deprivation. L929 cells were incubated for 30 minutes with maximally effective
concentrations of sodium azide (5 mM), berberine (50 µM), or media lacking glucose.
Uptakes were then measured in the presence and absence of maximally effective
concentration of AS (5.0 mM). The results are shown in Table 3.2. As expected, each
stimulant significantly activated glucose uptake, however, AS did not increase the effects
of the other stimulants. These results suggest that all stimulations, azide, berberine,
glucose deprivation, and AS share a common, rate-determining step in their mechanisms
of action.
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Table 3.2. Combined effects of AS with other activators
[AS]

Controls

+ Azide

+ Berb

+No glucose

0 mM

0.590.03

1.880.06

1.740.08

2.820.07

5.0 mM

1.830.09

2.210.09

1.880.04

3.000.10

L929 fibroblast cells were incubated for 30 minutes at 37 in DMEM media containing
either 0 mM glucose (no glucose), or 5.5 mM glucose containing no additions (control),
5.0 mM sodium azide, or 50 µM berberine. Glucose uptake was measured as described in
Materials and Methods in the presence and absence of 5.0 mM AS. Data are 2DG
uptake in nmol/10min/well  standard error. AS did not significantly increase the effects
of azide, berberine, or glucose deprivation.
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DISCUSSION
The role of nitric oxide (NO) as a biological second messenger has been well
established and this has led to an increased interest in the physiological action of other
redox forms of NO (Irvine et al., 2008). HNO, a one-electron reduction of NO, in
particular has garnered a lot of attention because it has interesting pharmacological
properties distinctly different from NO (Fukuto et al., 2005, 2009 & 2011, Irvine et al.,
2008; Switzer et al., 2009; paolocci et al., 2007, Miranda et al., 2003 and Wink et al.,
2003) . Of particular interest is the reaction of HNO with thiols. HNO can react with one
thiol to produce a N-hydroxysulfenamide which can either rearrange to form a
sulfinamide or react with a second thiol and produce a disulfide plus hydroxylamine
(Fukuto and Carington 2011). This chemistry appears to account for much of the
biological activity of HNO (Irvine et al., 2008; Donzelli et al., 2006, and Shen et al.,
2005).
In this study we report for the first time that AS very quickly activates the glucose
transport activity in L929 fibroblast cells, cells which only contain GLUT1 (Liong et al.,
1999). A 7.2-fold increase in activity occurs within 2 minutes of exposure to AS (see
Figure 3.4), which averages to a 4.0-fold activation after 10 minutes (see Figure 3.1, 3.2,
3.4). The maximum effective concentration is about 5.0 mM and higher concentrations
(20 mM) reduce this activation likely to additional reactions of HNO (see dose dependent
data in Figure 3.2 and the twice-exposed data in Figure 3.1). The activation by AS can be
blocked by three thiol active reagents, iodoacetamide, cinnamaldehye, and phenylarsine
oxide (Figure 3.6, Table 3.1) suggesting the activation is caused by a reaction of HNO
with cysteine residues. Possible targets for HNO are cysteine residues within GLUT1
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itself. Previous work in erthyrocytes has shown that GLUT1 can be activated by
disulfide bond formation within GLUT 1 (Carruthers et al., 2009) and computational
studies have indicated that within a hydrophobic environment such as the cell membrane,
the disulfide is the preferred product over the sulfinamide (Sherman et al., 2010). It is
not known if HNO is the actual agent responsible for physiological activation of GLUT1
or if this is purely a pharmacological phenomenon. The mM concentrations required to
activate GLUT1 are higher than µM concentrations needed to inhibit GAP (Lopez et al.,
2005 & 2007), but are similar to the range concentrations shown to enhance cardiac
function (Tochetti et al., 2007). Regardless, if HNO enhances glucose uptake via
activation of GLUT1 in cardiac tissue as well as L929 fibroblast cells, that would be an
added benefit in the use of HNO donors to treat heart failure. Future investigations
should be done to determine if HNO does indeed activate glucose uptake in cardiac cells.
Angeli’s salt can produce nitric oxide as well as HNO (Fukuto et al., 2005). This
study does not directly test for the potential involvement of the nitric oxide signaling
pathway in AS action. However, it seems unlikely that the causative agent for the
activation of glucose uptake in these cells is nitric oxide. A previous study showed that
the nitric oxide donor, sodium nitroprusside, did activate glucose uptake in L929 cells,
but it was about half as effective as AS (2 activation rather than 4) and required a much
longer activation time (30-45 min).
In addition to the interesting potential pharmacological effects of AS on glucose
uptake, this study also sheds light on a potential mechanism for the acute activation of
GLUT1 in L929 fibroblast cells. Once thought to be responsible only for basal glucose
uptake, it has been shown by a number of studies that this ubiquitously expressed
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transporter can be acutely activated by a variety of reagents (Shetty et al., 1993; Rubin et
al 2003; Barnes et al., 2002; Barros et al., 2001; Louters et al., 2006; Meyer et al., 2008;
Kumar et al., 2004 and Roelofs et al., 2006). It is known that the activation of GLUT1
occurs without a change in the concentration of the transporter in the plasma membrane,
but the change in GLUT1 that accounts for increased activity is not known. One
intriguing possible mechanism, based on Curruthers data in erythrocytes (Graybill et al.,
2006; Carruthers et al., 2009, Zottola et al., 1995; Herber et al., 1992, and Pessino et al.,
1991) and consistent with our data in L929 fibroblast cells, is outlined on Figure 3.7.
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Figure 3.7. Mechanism for activation of GLUT1.
In this model for activation of GLUT1 in L929 fibroblast cells, GLUT1 exists is a
number of states in the membrane ranging from a fully reduced monomer form which
would have the lowest transport activity to an oligomer (dimers, tetramers) which have
the highest activity.
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This model proposes that GLUT1 can exist in multiple states ranging from
monomers with reduced thiols to oligomers stabilized when GLUT1 is oxidized (internal
disulfide). The reduced monomer would have the lowest activity and the oligomer the
highest. Curruthers has demonstrated in erthryocytes that an internal disulfide bond forms
between Cys 347 and Cys 421, which stabilize the more active GLUT1 oligomer
(Carruthers et al., 2009 and Zottola et al., 1995). Furthermore, they have shown that
Cys 421 can be modified by iodoacetamide. While this study in L929 cells does not
provide direct evidence that GLUT1 is the target for HNO, the ability to block HNO
activation with iodoacetamide suggest that activation requires a disulfide bond formation
within some protein and the speed at which activation occurs makes GLUT1 itself the
likely target. Also, cinnamaldehye, a known to Michael acceptor thiols, partially
activates glucose uptake, but prevents the full, subsequent activation by AS, which can be
explained by cinnamaldehye adding to a thiol on GLUT1 activating the transporter, but
blocking the disulfide bond formation required to fully activate GLUT1 (Plaisier et al.,
2011). In addition, phenylarsine oxide, a substance that reacts with vicinal thiols also
activates, but prevents full activation by AS. Interestingly, PAO is typically a more
robust activator than cinnamonaldehye, and like AS, activates glucose uptake within
minutes (Scott et al., 2009). This suggests that the reaction of PAO with vicinal thiols
mimics a disulfide bond, but it may be that the bulky phenyl ring prevents
oligomerization and full activation of GLUT1.
We also show that AS does not further enhance the activation of other, slower
acting stimulators such as sodium azide, berberine or glucose deprivation (see Table 3.2).
A logical interpretation of this data is that these other methods of activation also stimulate
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disulfide bond formation. Future studies should investigate if thiol reactive substances
block activation by these agents.

CONCLUSSION
This study demonstrates that AS, likely through the release of HNO and subsequent
disulfide bond formation, very quickly activates the transport activity of GLUT1. The
activation of glucose uptake by HNO has not been previously noted and may also
contribute to the efficacy of using HNO as treatment for cardiac failure. These data are
consistent with a proposed mechanism for GLUT1 activation that involves the formation
of a disulfide bond within GLUT1.
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CHAPTER IV
MATERIALS AND METHODS
CHEMICALS
AS was a generous gift of Dr. John P. Toscano (Johns Hopkins University).
Phenylarsine oxide (PAO), cinnamaldehyde, cysteine, iodoacetamide, berberine, 2deoxy-D-glucose-[1,2-3H] (2DG) and D-mannitol-1-14C were purchased from the SigmaAldrich Chemical Company (St. Louis, MO, USA).
CELL CULTURE
L929 mouse fibroblast cells were obtained from the American Type Culture
Collection. To initiate each experiment, approximately 1.0 x 105 L929 fibroblast cells
were plated into each well of a 24-well culture-treated plate in 1.0 mL of low glucose (5.5
mM) DMEM (Dulbecco’s Modified Eagle Medium) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin. The cells were grown overnight at 37 °C in an
incubator supplied with humidified room air with 5% CO2. L6 myoblast cells were
grown in 24-well plates in DMEM (25.0 mM glucose) supplemented with 10% FBS. The
cells were then differentiated for six days by reducing FBS to 2%.
GENERAL EXPERIMENTAL DESIGN
In general, experiments had one or two phases, either a treatment phase followed
by a glucose uptake phase, or just the glucose uptake phase. Times for each phase are
indicated in the figure legends. To initiate an experiment with a treatment phase, the
media from cells in 24-well plates were removed and then incubated in 0.8 mL of fresh
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treatment media consisting of either low-glucose DMEM alone (0% FBS) (basal), or lowglucose DMEM plus the chemical of interest (see figure and table legends) or glucosefree DMEM (0% FBS) (activation by glucose deprivation). Cells were maintained at 37
°C for times indicated. If there was no treatment phase, cells were immediately incubated
in glucose uptake media (see below). AS was stored at -4 °C under nitrogen. In all
experiments using AS, the compound was weighed out and added to media at room
temperature immediately prior to distribution to the cells in the 24-well plate. The cells
were then returned to the incubator and the media allowed to warm to 37 °C.
In experiments designed to measure recovery from the effects of AS or Berberine,
the treatment phase was followed by a recovery period in which cells were washed and
returned to low-glucose media (0.8 mL) without AS or Berberine for varying times as
indicated in figure legend. Glucose uptake was measured as described below.
GLUCOSE UPTAKE ASSAY
Glucose uptake was measured using the radiolabeled glucose analog 2deoxyglucose (2DG) as previously described [37]. Briefly, the media was replaced with
0.3 mL of glucose-free HEPES buffer (140 mM NaCl, 5 mM KCl, 20 mM HEPES/Na
pH=7.4, 2.5 mM MgSO4, 1 mM CaCl2, 2 mM NaPyruvate, 1 mM mannitol)
supplemented with 1.0 mM (0.3 μCi/mL) 2-DG (1, 2-3H) and 1.0 mM (0.02 μCi/mL)
mannitol (1-14C). Uptake media was supplemented with additional compounds, such as
AS, as indicated in the figure and table legends. After a 10-minute incubation, cells were
washed twice with cold glucose-free HEPES. The cells were lysed in 0.5 mL lysis buffer
(10 mM Tris pH=7.4, 150 mM NaCl, 5 mM EDTA, 1.0% triton X-100, 0.4% SDS) and
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the 3H-2 DG uptake with 14C-mannitol as the extracellular marker was measured using
scintillation spectrometry. Uptake of 14C-mannitol only occurs if the cell membrane is
compromised. Therefore, the use of a double-labeled uptake solution allows us to both
measure surface binding and monitor potential toxic effects of the experimental
treatments that would compromise the cell membrane.
STATISTICAL ANALYSIS
Experimental conditions were repeated in triplicate or quadruplicate and glucose
uptake was measured and reported as nmol/10 min/well ±standard error. Statistical
significance was determined by either ANOVA followed by a post-hoc Dunnett test (dose
and time dependent effects) or a two-tailed t-test. Statistical significance is reported at P<
0.01 or P<0.05. Experiments were repeated several times and results from representative
experiments are reported.
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